CO5180585A1 - Formulaciones en granulos de quetiapina, su preparacion y su uso - Google Patents

Formulaciones en granulos de quetiapina, su preparacion y su uso

Info

Publication number
CO5180585A1
CO5180585A1 CO00070974A CO00070974A CO5180585A1 CO 5180585 A1 CO5180585 A1 CO 5180585A1 CO 00070974 A CO00070974 A CO 00070974A CO 00070974 A CO00070974 A CO 00070974A CO 5180585 A1 CO5180585 A1 CO 5180585A1
Authority
CO
Colombia
Prior art keywords
granules
bed
formulations
preparation
formulation
Prior art date
Application number
CO00070974A
Other languages
English (en)
Spanish (es)
Inventor
Brown Daniel Boyd
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5180585(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5180585A1 publication Critical patent/CO5180585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CO00070974A 1999-09-21 2000-09-19 Formulaciones en granulos de quetiapina, su preparacion y su uso CO5180585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation

Publications (1)

Publication Number Publication Date
CO5180585A1 true CO5180585A1 (es) 2002-07-30

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00070974A CO5180585A1 (es) 1999-09-21 2000-09-19 Formulaciones en granulos de quetiapina, su preparacion y su uso

Country Status (37)

Country Link
US (3) US6599897B1 (https=)
EP (1) EP1218009B1 (https=)
JP (1) JP2003509461A (https=)
KR (1) KR100748823B1 (https=)
CN (3) CN1188130C (https=)
AR (1) AR032596A1 (https=)
AT (1) ATE288272T1 (https=)
AU (1) AU776292B2 (https=)
BG (1) BG65469B1 (https=)
BR (1) BR0014107A (https=)
CA (1) CA2383131A1 (https=)
CO (1) CO5180585A1 (https=)
CZ (1) CZ301585B6 (https=)
DE (1) DE60017923T2 (https=)
DK (1) DK1218009T3 (https=)
EE (1) EE200200150A (https=)
EG (1) EG24226A (https=)
ES (1) ES2235941T3 (https=)
GB (2) GB9922271D0 (https=)
HK (1) HK1047706B (https=)
HU (1) HUP0203531A3 (https=)
IL (2) IL148440A0 (https=)
IS (1) IS2139B (https=)
MX (1) MXPA02002627A (https=)
MY (1) MY130208A (https=)
NO (1) NO320908B1 (https=)
NZ (1) NZ517549A (https=)
PL (1) PL198824B1 (https=)
PT (1) PT1218009E (https=)
RU (1) RU2256453C2 (https=)
SI (1) SI1218009T1 (https=)
SK (1) SK286884B6 (https=)
TR (1) TR200200716T2 (https=)
TW (1) TWI226832B (https=)
UA (1) UA73529C2 (https=)
WO (1) WO2001021179A1 (https=)
ZA (1) ZA200201709B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
WO2006117700A2 (en) * 2005-04-21 2006-11-09 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
CA2657202A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
WO2008052354A1 (en) * 2006-11-03 2008-05-08 University Of Saskatchewan Method of treating demyelination diseases
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
ATE480227T1 (de) * 2007-02-14 2010-09-15 Lesvi Laboratorios Sl Pharmazeutische zusammensetzungen mit quetiapinfumarat
ES2700994T3 (es) * 2008-02-27 2019-02-20 Intercontinental Great Brands Llc Confitería de multirregión
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
AU2021263558B2 (en) * 2020-04-29 2026-02-26 Stepan Company Solid compositions containing amine, protonated amine or quaternary ammonium compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
ES2054259T3 (es) * 1989-08-31 1994-08-01 Takeda Chemical Industries Ltd Composicion de vitamina b12.
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
ATE163927T1 (de) * 1992-11-09 1998-03-15 Knoll Ag 1,4-benzothiazepine verwendbar als neurologische mittel
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
HUP0203531A3 (en) 2004-12-28
PL357369A1 (en) 2004-07-26
SK3722002A3 (en) 2002-07-02
ZA200201709B (en) 2003-05-28
HK1047706A1 (en) 2003-03-07
BR0014107A (pt) 2002-08-20
MXPA02002627A (es) 2002-07-30
SI1218009T1 (en) 2005-06-30
UA73529C2 (uk) 2005-08-15
SK286884B6 (sk) 2009-07-06
IS2139B (is) 2006-08-15
IS6308A (is) 2002-03-19
EP1218009A1 (en) 2002-07-03
AU7302300A (en) 2001-04-24
CN1626094A (zh) 2005-06-15
MY130208A (en) 2007-06-29
IL148440A (en) 2007-07-04
TR200200716T2 (tr) 2002-06-21
NO320908B1 (no) 2006-02-13
TWI226832B (en) 2005-01-21
JP2003509461A (ja) 2003-03-11
NO20021394D0 (no) 2002-03-20
KR100748823B1 (ko) 2007-08-13
CN1899288A (zh) 2007-01-24
CN1188130C (zh) 2005-02-09
NZ517549A (en) 2003-10-31
EE200200150A (et) 2003-04-15
CN1374867A (zh) 2002-10-16
EP1218009B1 (en) 2005-02-02
GB0021406D0 (en) 2000-10-18
US20060159768A1 (en) 2006-07-20
DK1218009T3 (da) 2005-05-09
EG24226A (en) 2008-11-10
BG106509A (en) 2002-12-29
GB9922271D0 (en) 1999-11-17
WO2001021179A1 (en) 2001-03-29
US7022692B2 (en) 2006-04-04
PL198824B1 (pl) 2008-07-31
ATE288272T1 (de) 2005-02-15
DE60017923D1 (de) 2005-03-10
IL148440A0 (en) 2002-09-12
US6599897B1 (en) 2003-07-29
DE60017923T2 (de) 2006-01-12
PT1218009E (pt) 2005-05-31
CA2383131A1 (en) 2001-03-29
KR20020033186A (ko) 2002-05-04
US20040228914A1 (en) 2004-11-18
CZ301585B6 (cs) 2010-04-21
ES2235941T3 (es) 2005-07-16
HUP0203531A2 (hu) 2003-02-28
NO20021394L (no) 2002-03-20
AU776292B2 (en) 2004-09-02
HK1047706B (en) 2005-06-10
CZ2002974A3 (cs) 2002-06-12
CN1331472C (zh) 2007-08-15
BG65469B1 (bg) 2008-09-30
AR032596A1 (es) 2003-11-19
RU2256453C2 (ru) 2005-07-20

Similar Documents

Publication Publication Date Title
CO5180585A1 (es) Formulaciones en granulos de quetiapina, su preparacion y su uso
EE05378B1 (et) LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
NO20020975L (no) Retardierte administreringsformer inneholdende tramadolsakkarinat
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
DE60037395D1 (de) Herstellung eines halbleiter-bauelementes
ES2182079T3 (es) Composiciones farmaceuticas de liberacion sostenida que contienen un derivado de dibenzotiazepina.
EP1229820A4 (en) CLOSURE OF TUBULAR, ANATOMICAL STRUCTURES THROUGH ENERGY INPUT
ES2175799T3 (es) Forma de dosificacion para administracion en aerosol.
AR042937A2 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
BR0107869A (pt) Composições farmacêuticas eletrogiradas
PL362692A1 (en) Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
BR9611263A (pt) Pastilha de limpesa para vaso sanitário.
CL2008000134A1 (es) Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
PE20010623A1 (es) Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
AR027571A1 (es) Derivados de cromano como compuestos estrogenicos y su uso en la fabricacion de medicamentos para tratamientos relacionados con los receptores deestrogenos
EP1339622A4 (en) WAFER CARRIER WITH STACKED ADAPTER PLATE
AR013282A1 (es) Articulo absorbente desechable formado anatomicamente con alta resiliencia del lobulo
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
RU99107244A (ru) Лекарственная форма для фиксации съемных протезов
ITMI20000380A0 (it) Uso di composti fluorurati per conferire proprieta' release
IT1313383B1 (it) Struttura efficiente di integratore a capacita' commutate integrato
HUP0302344A3 (en) A process for the preparation of alpha-n-acyl alpha' chloroketones
IT9020943A0 (it) Composizione farmaceutica per uso orale a rilascio modificato di antiinfiammatori non steroidei

Legal Events

Date Code Title Description
FC Application refused